Edition:
United Kingdom

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

27.66USD
5:10pm GMT
Change (% chg)

$-0.70 (-2.47%)
Prev Close
$28.36
Open
$28.58
Day's High
$28.58
Day's Low
$27.42
Volume
50,891
Avg. Vol
140,485
52-wk High
$41.75
52-wk Low
$24.74

Latest Key Developments (Source: Significant Developments)

Aimmune Therapeutics Inc QTRLY Loss Per Share $0.91
Wednesday, 8 Aug 2018 

Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.AIMMUNE THERAPEUTICS INC QTRLY LOSS PER SHARE $0.91.AIMMUNE THERAPEUTICS INC - CASH, CASH EQUIVALENTS, AND INVESTMENTS TOTALED $295.9 MILLION AT JUNE 30, 2018.  Full Article

Aimmune Extends Supply Agreement With Golden Peanut And Tree Nuts For Experimental Allergy Treatment
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY.AIMMUNE THERAPEUTICS INC - ‍NEWLY EXPANDED GLOBAL AGREEMENT SECURES EXCLUSIVE SUPPLY RELATIONSHIP THROUGH 2033​.AIMMUNE THERAPEUTICS INC - AR101 IS CURRENTLY IN PHASE 3 CLINICAL TRIALS, WITH PIVOTAL TOPLINE DATA EXPECTED IN FEBRUARY.AIMMUNE THERAPEUTICS INC - ‍AS PART OF AGREEMENT, AIMMUNE HAS GRANTED ADM A 300,000-SHARE EQUITY STAKE IN AIMMUNE​.AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY.AIMMUNE THERAPEUTICS - ‍ AGREEMENT GIVES CO EXCLUSIVE ACCESS TO ADDITIONAL GOLDEN PRODUCTS THAT COULD BE DEVELOPED INTO PEANUT ORAL IMMUNOTHERAPIES​.  Full Article

Aimmune Therapeutics says ‍CEO Stephen Dilly plans to retire by end of 2018​
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Aimmune Therapeutics Inc :Aimmune Therapeutics Inc announces third quarter 2017 financial results and planned retirement of CEO by the end of 2018.Aimmune Therapeutics Inc - ‍CEO Stephen Dilly plans to retire by end of 2018​.Aimmune Therapeutics Inc - ‍Aimmune will initiate a search for a successor CEO​.Aimmune Therapeutics Inc - ‍Dilly will continue as Aimmune's CEO until his replacement joins company and will be available through a transition period​.Aimmune Therapeutics Inc qtrly ‍on a per share basis, net loss for quarter was $0.63​.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Aimmune Therapeutics Inc - ‍expects last double-blind, placebo-controlled food challenge in phase 3 palisade trial of ar101 will be conducted in Dec. 2017​.Aimmune Therapeutics Inc - ‍cash, cash equivalents, and investments were $212.0 million at Sept 30, 2017, compared to $282.5 million at december 31, 2016​.Aimmune Therapeutics Inc - ‍top-line data from phase 3 palisade trial of ar101 will be available in q1 of 2018​.  Full Article

Photo

Nestle raises stake in food allergy drug developer Aimmune

The health science arm of Nestle SA will pay $98 million (76 million pounds) to raise its stake in Aimmune Therapeutics Inc , the drug developer said, as it prepares to submit a marketing application for its peanut allergy drug by the end of the year.